KalVista Pharmaceuticals SEC filings document 8-K disclosures for a commercial-stage pharmaceutical company focused on oral rare-disease therapies. The filings cover results of operations and financial condition, Regulation FD materials, product-revenue updates tied to EKTERLY, and the company’s Nasdaq-listed common stock.
The filing record also includes governance and compensation disclosures, board committee changes, executive appointments, material definitive agreements, and capital-structure actions. Financing disclosures include the completed sale of 3.250% convertible senior notes due 2031, while other reports describe exhibit filings, furnished press releases, Inline XBRL cover data, and formal disclosure treatment under the Exchange Act.
KalVista Pharmaceuticals agreed to be acquired by Chiesi Group in an all-cash transaction. Chiesi will launch a tender offer to buy all outstanding KalVista shares for $27.00 per share, implying a total deal value of about $1.9 billion.
The offer is conditioned on a majority of shares being tendered, antitrust and foreign investment clearances, and customary accuracy, covenant and no–material-adverse-effect conditions. After the tender offer, a back-end merger under Section 251(h) of Delaware law will make KalVista a wholly owned Chiesi subsidiary.
KalVista’s board unanimously approved the merger agreement and recommends stockholders tender their shares. The agreement includes typical non-solicitation and fiduciary out provisions and a $66.4 million termination fee payable to Chiesi in specified circumstances. The parties expect closing in Q3 2026, subject to conditions.
KalVista Pharmaceuticals chief medical officer Paul K. Audhya reported routine equity compensation activity and a related tax sale. On April 16, 6,250 restricted stock units vested into the same number of common shares at no cost, as part of a scheduled RSU vesting plan. A total of 2,686 common shares were then sold at an average price of $20.2163 solely to cover tax withholding obligations through a non-discretionary sell-to-cover arrangement. After these transactions, he directly holds 142,547 shares of common stock and 93,750 unvested RSUs that continue to vest quarterly, subject to continued service.
KalVista Pharmaceuticals Chief Commercial Officer Nicole Sweeny reported routine equity compensation activity and a related tax sale. On April 16, 2026, 6,250 restricted stock units converted into an equal number of common shares at no cost, reflecting RSU vesting. On April 17, 2026, 1,862 common shares were sold at $20.2163 per share solely to cover tax withholding obligations in a non-discretionary “sell to cover” transaction. After these transactions, Sweeny directly held 51,391 shares of KalVista common stock. The RSU award vests in 16 equal quarterly installments starting on April 16, 2026, subject to continued service.
KalVista Pharmaceuticals Chief Financial Officer Brian Piekos reported routine equity compensation activity. On April 16, 2026, 6,250 restricted stock units (RSUs) converted into the same number of common shares for no cash consideration, reflecting scheduled vesting. On April 17, 2026, he sold 1,862 common shares at $20.2163 per share in an open-market transaction specifically to cover tax withholding obligations from the RSU vesting, described as a nondiscretionary “sell to cover” sale. After these transactions, he directly held 18,150 common shares, and 93,750 RSUs remained outstanding, which continue to vest quarterly in 1/16 increments starting April 16, 2026, subject to continued service.
KalVista Pharmaceuticals CEO Benjamin L. Palleiko reported routine equity compensation activity and a related tax sale. On April 16, 2026, restricted stock units vested and were settled into 20,312 shares of Common Stock at $0.00 per share, reflecting a compensation-related share delivery. To cover tax withholding obligations from this RSU vesting, he then sold 9,550 shares of Common Stock at an average price of $20.2163 per share on April 17, 2026 in a "sell to cover" transaction described as non-discretionary. Following these transactions, he holds 462,577 Common Stock shares directly.
KalVista Pharmaceuticals’ major shareholder funds reported open-market sales of 214,631 shares of Common Stock. The transactions were executed on March 25–26 at prices between approximately $16.95 and $19.12 per share through entities affiliated with Venrock Healthcare Capital Partners.
After these sales, the affiliated funds continue to hold about 5,089,354 shares indirectly. The filing clarifies that management entities and individuals associated with these funds may be deemed to beneficially own these securities only to the extent of any indirect pecuniary interest.
KalVista Pharmaceuticals filed a Transition Report on Form 10-KT for the eight-month fiscal transition period May 1, 2025 through December 31, 2025, noting a change in fiscal year end to December 31. The company launched EKTERLY® (sebetralstat) after FDA approval on July 3, 2025 and lists additional approvals in the E.U., U.K., Switzerland, Japan, Australia and Singapore. KalVista states it began U.S. and German commercial operations, has established regional partnerships and entered a royalty financing arrangement providing an upfront $100.0 million plus a $22.0 million one-time payment. Cash and cash equivalents were $229.3 million as of December 31, 2025, and shares outstanding were 51,222,487 as of March 18, 2026.
KalVista Pharmaceuticals reported results for the eight-month transition period ended December 31, 2025, reflecting its shift to a calendar fiscal year. The company generated $49.1 million in global net product revenue from EKTERLY, the first and only oral on-demand treatment for hereditary angioedema.
Adoption is highlighted by 1,702 US patient start forms from launch through February and launches in markets including Germany and Japan through partner Kaken. Despite this growth, KalVista reported a net loss of $109.5 million and basic and diluted net loss per share of $2.03 for the period.
On the balance sheet, cash, cash equivalents and marketable securities were $300.2 million as of December 31, 2025, with total assets of $335.4 million and total liabilities of $338.1 million, resulting in a modest stockholders’ deficit. Management reiterated plans to expand EKTERLY access and advance pediatric filings.
KalVista Pharmaceuticals CEO Benjamin L. Palleiko reported routine equity compensation activity and a related tax sale. On March 6, 2026, he exercised 15,625 Restricted Stock Units (RSUs), receiving an equal number of KalVista common shares for no cash consideration. The RSUs vest in 16 equal quarterly installments starting June 6, 2024, subject to continued service. On March 9, 2026, he sold 6,693 common shares at a weighted average price of $16.0814 per share solely to cover tax withholding obligations from the RSU vesting, described as a non-discretionary “sell to cover” transaction. After these transactions, he holds 451,815 common shares directly and 125,001 RSUs, giving him a substantial ongoing equity stake.
KalVista Pharmaceuticals chief medical officer Paul K. Audhya reported a mix of equity award vesting and tax-related share sales. He exercised and settled restricted stock units (RSUs) into 6,250 and 5,000 shares of common stock at no cost on separate days, reflecting routine equity compensation vesting where each RSU converts into one share.
To cover tax withholding from these RSU settlements, he sold 5,354 shares of common stock in an open-market "sell to cover" transaction at a weighted average price of $15.5668 per share, described as non-discretionary. After these transactions, he held 138,983 shares of common stock directly, with RSU awards continuing to vest in equal sixteenth installments on each quarterly anniversary of the vesting commencement date.